First-in-class hiPSC derived Endothelial cell therapy for cardiovascular disease

We are a clinical-stage biotech company developing regenerative cell therapies for cardiovascular disease. Our iPSC-derived endothelial cell therapy is in Phase I trials for PAD—the world’s first clinical study of its kind. We are also advancing directly reprogrammed endothelial cells (rECs) as next-generation vascular therapeutics in collaboration with Emory University.